Peptide News Digest

#Thymosin

2 stories

Research · View digest

Review of 30 Studies Finds Thymosin Raised Some Immune Counts in Colorectal Cancer Patients but Evidence Is Too Weak for Routine Use

Researchers at the First Affiliated Hospital of Henan University of Chinese Medicine reviewed 30 studies with 2,514 colorectal cancer patients, including 25 randomized trials, in which thymosin preparations were added to the same anticancer treatment, publishing in Frontiers in Oncology. After surgery, thymosin was linked to higher CD4 percentages, CD4/CD8 ratios, and natural killer cell percentages, and some trials reported better performance scores, but effects on neutropenia were inconclusive and only one trial gave comparable survival data. Certainty was low or very low, and the authors say current evidence does not support routine use.

Research · View digest

Frontiers in Aging 2026 Review: Therapeutic Peptides in Gerontology — Mechanisms and Applications for Healthy Aging

A 2026 Frontiers in Aging review consolidates the case for therapeutic peptides as gerontology agents, mapping mechanisms across mitochondrial-derived peptides (MOTS-c, humanin), thymic peptides (thymosin alpha-1), wound-and-tissue-repair peptides (BPC-157, TB-500), copper peptides (GHK-Cu), and growth-hormone secretagogues (CJC-1295, ipamorelin). The review frames the longevity peptide field as a clinical category that now sits alongside GLP-1 metabolic medicine — driven by Hims & Hers' 2026 longevity-specialty launch, Drexel's May 5 Q&A on peptide popularity, and the FDA Category 2 removal of 12 peptides on April 22. The piece also flags that BPC-157, TB-500, and most wellness peptides still lack published human RCTs, with clinical use largely based on case reports and preclinical mechanistic rationale.